Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06407297
NA

UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetes

Sponsor: Shanghai Changzheng Hospital

View on ClinicalTrials.gov

Summary

The aim is to investigate the safety and tolerability of intravenous infusion of allogeneic umbilical cord mesenchymal stem cells in pediatric patients diagnosed with newly onset type 1 diabetes

Official title: Investigation of Dose Escalation and Cohort Expansion Study on the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells(UCMSCs) Combined With Standard Therapy for Newly Diagnosed Type 1 Diabetes

Key Details

Gender

All

Age Range

8 Years - 18 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2024-05-23

Completion Date

2026-05-01

Last Updated

2024-12-27

Healthy Volunteers

Yes

Interventions

DRUG

UCMSCs

Peripheral intravenous infusion of umbilical cord mesenchymal stem cells

DRUG

Placebo

Peripheral intravenous infusion of Placebo

Locations (1)

Shanghai Changzheng Hospital

Shanghai, Shanghai Municipality, China